On Cancer

Filter by Tag

Pictured: Vincent Laudone and James Eastham

Perspective

When Do No Harm Means Do Nothing: Managing Risks

By James Eastham, MD and Vincent Laudone, MD
Friday, September 20, 2013

An earlier post about active surveillance as a management strategy for prostate cancer generated an engaged and meaningful discussion on this blog, especially about the risks of “doing nothing.” Here we take a closer look at the concept of risk.

Tags: Cancer Care; Treatment; Prostate Cancer

Pictured: Vincent Laudone & James Eastham

Perspective

When “Do No Harm” Means “Do Nothing”

By James Eastham, MD and Vincent Laudone, MD
Wednesday, August 14, 2013

Active surveillance is the most appropriate management strategy for many men with prostate cancer, but often this option is never mentioned.

Tags: Cancer Care; Treatment; Prostate Cancer

Honor

Pramod Sogani Inaugurated As President of the American Urological Association

By Media Staff | Monday, July 1, 2013

Memorial Sloan-Kettering urologic surgeon Pramod Sogani has been inaugurated as President of the American Urological Association. In this Q&A he discusses his goals and his new role.

Tags: Cancer Care; Bladder Cancer; Kidney Cancer; Prostate Cancer; Testicular Cancer

Charles Sawyers, Kenneth Offit, and Larry Norton

Honor

Three Memorial-Sloan Kettering Researchers Receive Special Awards by the American Society of Clinical Oncology

By Eva Kiesler, PhD, Science Writer/Editor | Wednesday, May 22, 2013

Charles Sawyers, Larry Norton, and Kenneth Offit are being honored with special awards at the annual meeting of the world’s leading professional organization for cancer physicians and researchers.

Tags: Cancer Care; Research; Targeted Therapy; Breast Cancer; Ovarian Cancer; Prostate Cancer

In the Lab

Research Suggests a New Approach for Overcoming Resistance to a Targeted Therapy for Prostate Cancer

By Julie Grisham, MS, Science Writer/Editor | Tuesday, April 30, 2013

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

Tags: Cancer Biology; Cancer Care; Lab Research; Research; Drug Discovery; Targeted Therapy; Prostate Cancer

Finding

A Single Early PSA Test Found to Predict Long-Term Risk of Aggressive Prostate Cancer

By Allyson Collins, MS, Science Writer/Editor | Wednesday, April 17, 2013

A study led by Memorial Sloan-Kettering investigators indicates nearly half of all prostate cancer deaths by age 75 occur in a small group of men with high PSA levels at age 45.

Tags: Cancer Care; Research; Health Outcomes & Statistics Research; PSA Testing; Diagnosis; Screening; Prostate Cancer

Q&A

Department of Surgery Chair Peter Scardino on Smarter Screening for Prostate Cancer

By Esther Napolitano, BS, Science Writer/Editor | Thursday, March 14, 2013

Dr. Scardino discusses strategies for how physicians and patients can make the best use of PSA testing and prostate cancer treatment.

Tags: Cancer Care; PSA Testing; Diagnosis; Screening; Prostate Cancer

Q&A

Urologist John Mulhall Explains Strategies for Addressing Sexual Health Concerns for Men with Cancer

By Media Staff | Friday, March 8, 2013

Dr. Mulhall, director of Memorial Sloan-Kettering’s Male Sexual and Reproductive Medicine Program, explains common concerns about male sexual health and offers advice for men and their partners.

Tags: Cancer Care; Counseling & Support; Survivorship; Sexual Health; Bladder Cancer; Prostate Cancer; Testicular Cancer

Video

Meet Urologic Cancer Surgeon Raul Parra

By Memorial Sloan-Kettering | Wednesday, March 6, 2013

Dr. Parra, who practices at Memorial Sloan-Kettering Basking Ridge, treats prostate, kidney, and bladder cancers with the goal of extending the lives of patients, and giving them the best possible quality of life.

Tags: Cancer Care; Bladder Cancer; Surgery; Treatment; Kidney Cancer; Prostate Cancer

Pictured: David Finley & Maria Teresa Ruiz Tsukazan

Feature

Robot-Assisted Surgery at Memorial Sloan-Kettering

By Celia Gittelson, BA | Monday, February 25, 2013

Our doctors introduce and apply advanced technologies in minimal-access surgery to benefit patients.

Tags: Cancer Care; Robotic Surgery; Surgery; Colorectal Cancer; Esophageal Cancer; Kidney Cancer; Lung Cancer; Prostate Cancer; Uterine Cancer

Honor

Physician-Scientist Charles Sawyers Awarded Breakthrough Prize in Life Sciences

By Media Staff | Wednesday, February 20, 2013

Charles Sawyers, Chair of Memorial Sloan-Kettering’s Human Oncology and Pathogenesis Program, is a recipient of the inaugural $3 million prize for groundbreaking achievements in scientific research.

Tags: Research; Drug Discovery; Targeted Therapy; Treatment; Leukemias; Prostate Cancer

Video

Meet Urologic Surgeon Bernard Bochner

By Memorial Sloan-Kettering | Friday, January 11, 2013

Dr. Bochner – who specializes in treating people with prostate, bladder, and kidney cancers – discusses the importance of a multidisciplinary team approach to delivering high-quality care.

Tags: Cancer Care; Bladder Cancer; Surgery; Kidney Cancer; Prostate Cancer

In the Clinic

Medication Used Before, During, and After Radiation Treatment Helps Men with Prostate Cancer Maintain Overall Sexual Function

By Andrea Peirce, BA and Media Staff
Friday, November 30, 2012

Study signals hope for maintaining sexual function in men undergoing radiation treatment for prostate cancer.

Tags: Cancer Care; Clinical Research; Clinical Trials; Sexual Health; Radiation Therapy; Prostate Cancer

In the Lab

New Imaging Agent Could Improve Prostate Cancer Diagnosis and Treatment

By Eva Kiesler, PhD, Science Writer/Editor | Thursday, November 15, 2012

Researchers at Memorial Sloan-Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.

Tags: Cancer Biology; Lab Research; Research; Medical Technology; Targeted Therapy; Prostate Cancer

Pictured: Charles Sawyers & Howard Scher

Announcement

Targeted Therapy for Advanced Prostate Cancer Receives FDA Approval

By Memorial Sloan-Kettering | Friday, August 31, 2012

Enzalutamide, a targeted therapy co-invented by a Memorial Sloan-Kettering investigator, has received FDA approval for the treatment of men with metastatic prostate cancer.

Tags: Cancer Care; Research; Targeted Therapy; Treatment; Prostate Cancer